In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

Katherine Young(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mary Motyl(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fred Racine(Merck & Co., Inc., Rahway, NJ, USA (United States)), Carl J. Balibar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Artjohn Villafania(Merck & Co., Inc., Rahway, NJ, USA (United States)), Timothy A. Blizzard(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rumin Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nichelle Hairston(Merck & Co., Inc., Rahway, NJ, USA (United States)), Milton L. Hammond(Merck & Co., Inc., Rahway, NJ, USA (United States)), Douglas Wisniewski(Merck & Co., Inc., Rahway, NJ, USA (United States)), Susan L. Raghoobar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ronald E. Painter(Merck & Co., Inc., Rahway, NJ, USA (United States)), Daniel F. Sahm(Micro Focus (United States)), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States))
BMC Microbiology
July 4, 2019
Cited by 126


Related Papers